Related Experiment Videos
Do selective cyclo-oxygenase-2 inhibitors have a future?
1Department of Rheumatology, Pellegrin Hospital, Victor Segalen University, Bordeaux, France. bernard.bannwarth@u-bordeaux2.fr
Drug Safety
|March 1, 2005
Summary
The withdrawal of rofecoxib highlighted cardiotoxicity concerns with COX-2 inhibitors. This review examines the cardiovascular risks of COX-2 inhibitors and NSAIDs, and the future of selective COX-2 inhibitors.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Safety
Background:
- Rofecoxib withdrawal in 2004 due to cardiotoxicity.
- Safety concerns surrounding other cyclo-oxygenase (COX)-2 inhibitors, notably valdecoxib.
Discussion:
- Examining the predictability of rofecoxib's cardiotoxicity prior to its withdrawal.
- Assessing whether the thrombotic risk associated with COX-2 inhibitors is a class effect.
- Investigating potential cardiovascular thrombosis risks with conventional non-steroidal anti-inflammatory drugs (NSAIDs).
Key Insights:
- Cardiotoxicity of rofecoxib may have been predictable.
- Thrombotic risk might be a class effect for COX-2 inhibitors.
- Conventional NSAIDs may also pose cardiovascular risks.
Outlook:
- The future viability of selective COX-2 inhibitors in light of safety concerns.
- Implications for clinicians, pharmaceutical companies, and regulatory bodies regarding drug safety evaluations.